Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
But NASH Candidate Generates Interest
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.
You may also be interested in...
ANGPTL3 Road Has Some Potholes As Pfizer Sends Vupanorsen Back To Ionis
The decision followed the November 2021 announcement that while a Phase IIb study hit its primary endpoint, the magnitude of benefit was too small and adverse event rate too high.
Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate
GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.
$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.